Table 2.
Variables associated with lymphovascular space invasion in ovarian cancer
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Case number | OR (95% CI) | P | OR (95% CI) | P | |
| Training set cohort | |||||
| Tumor stage (per stage) | 13 vs. 12 vs. 103 | 6.54 (3.13–13.7) | <0.001 | 3.90 (1.46–10.4) | 0.007 |
| Any nodal metastasis (yes vs. no) | 74 vs. 53 | 18.1 (5.06–65.0) | <0.001 | 7.99 (1.98–32.1) | 0.003 |
| Pelvic lymph nodes (yes vs. no) | 66 vs. 58 | 22.6 (5.03–101) | <0.001 | ||
| Para-aortic lymph nodes (yes vs. no) | 31 vs. 33 | 22.1 (2.68–182) | 0.004 | ||
| High-grade serous carcinoma (yes vs. no) | 93 vs. 34 | 3.81 (1.54–9.43) | 0.004 | 0.78 | |
| Validation cohort | |||||
| Tumor stage (per stage) | 40 vs. 22 vs. 31 | 2.45 (1.46–4.11) | 0.001 | 0.16 | |
| Any nodal metastasis (yes vs. no) | 17 vs. 76 | 9.77 (2.09–45.7) | 0.004 | 5.74 (1.13–29.2) | 0.035 |
| High-grade serous carcinoma (yes vs. no) | 28 vs. 61 | 3.37 (1.28–8.83) | 0.014 | 0.16 | |
Logistic regression test for presence of tumoral LVSI (yes vs. no). Examined all the collected variables and only significant variables are listed. OR, odds ratio; 95% CI, 95% confidence interval; LVSI, lymphovascular space invasion.